Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells

• US 8,263,065 B2
• Filed: 09/29/2008
• Issued: 09/11/2012
• Est. Priority Date: 09/28/2007
• Status: Active Grant

• Current Assignee: Celularity, Inc.
• Original Assignee: Anthrogenesis Corporation (Bristol-Myers Squibb Company)
• Inventors: Hariri, Robert J., Heidaran, Mohammad A., Kang, Lin, Padliya, Neerav Dilip, Pal, Ajai, Voskinarian-Berse, Vanessa, Zeitlin, Andrew, Zhang, Xiaokui
• Primary Examiner(s): Aeder, Sean
• Application Number:
  US12/240,956
• Publication Number:
  US 20090252710A1
• Time in Patent Office: 1,443 Days
• Field of Search: None
• US Class Current: 424/93.1
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 2239/48 Blood cells, e.g. leukemia or lymphoma
• CPC Class Codes: A61K 2239/49 Breast
• CPC Class Codes: A61K 2239/52 Intestine
• CPC Class Codes: A61K 35/17 Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes when activated by a specific antigen A61K39/00
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61K 39/4613 Natural-killer cells [NK or NK-T]
• CPC Class Codes: A61K 39/4644 Cancer antigens
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 5/0646 Natural killers cells [NK], NKT cells

Abstract

Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.

Claims

1. A method of suppressing the proliferation of tumor cells comprising contacting the tumor cells with human placental perfusate cells, wherein said placental perfusate cells comprise CD56⁺ placental intermediate natural killer (PINK) cells.

2. The method of claim 1, wherein the tumor cells are blood cancer cells.

3. The method of claim 1, wherein the tumor cells are solid tumor cells.

4. The method of claim 1, wherein the tumor cells are primary ductal carcinoma cells, leukemia cells, acute T cell leukemia cells, chronic myeloid lymphoma (CML) cells, acute myelogenous leukemia cells, chronic myelogenous leukemia (CML) cells, lung carcinoma cells, colon adenocarcinoma cells, histiocytic lymphoma cells, colorectal carcinoma cells, colorectal adenocarcinoma cells, or retinoblastoma cells.

5. The method of claim 1, wherein said perfusate comprises a culture medium.

6. The method of claim 1, wherein said perfusate has been treated to remove a plurality of erythrocytes.

7. The method of claim 1, wherein said contacting is contacting in vitro.

8. The method of claim 1, wherein said contacting is contacting in vivo.

9. The method of claim 8, wherein said contacting is in a human.

10. The method of claim 1, wherein said plurality of placental perfusate cells are total nucleated cells from placental perfusate.

11. The method of claim 1, wherein said placental perfusate cells comprise at least about 50% CD56⁺ placental cells.

29. The method of claim 11, wherein said placental perfusate cells comprise at least about 50% CD56⁺, CD16⁻

PINK cells.

31. The method of claim 1, wherein said PINK cells express one or more of the microRNAs hsa-miR-100, hsa-miR-127, hsa-miR-211, hsa-miR-302c, hsa-miR-326, hsa-miR-337, hsa-miR-497, hsa-miR-512-3p, hsa-miR-515-5p, hsa-miR-517b, hsa-miR-517c, hsa-miR-518a, hsa-miR-518e, hsa-miR-519d, hsa-miR-520g, hsa-miR-520h, hsa-miR-564, hsa-miR-566, hsa-miR-618, or hsa-miR-99a at a detectably higher level than peripheral blood natural killer cells.

34. The method of claim 1, wherein said PINK cells express one or more of aminopeptidase N protein, apolipoprotein E protein, atrophin-1 interacting protein 1, innexin inx-3 protein, integrin alpha-2 precursor protein, integrin beta-5 precursor, mast cell surface glycoprotein GP49B precursor protein, or ryanodine receptor 1 protein;

and do not express one or more of fibroblast growth factor receptor 4 precursor protein, immunity-associated nucleotide 4-like protein, integrin alpha-L precursor protein, integrin beta 2 precursor protein, integrin beta 4 precursor protein, membrane-bound lytic murein transglycosylase D precursor protein, oxysterol binding protein-related protein 8, or perforin 1 precursor 1 protein.

12. A method of suppressing the proliferation of tumor cells comprising contacting the tumor cells with a plurality of CD56⁺, CD16⁻

PINK cells.

13. The method of claim 12, wherein said contacting takes place in vitro.

14. The method of claim 12, wherein said contacting takes place in vivo.

15. The method of claim 14, wherein said contacting takes place in a human.

16. The method of claim 12, wherein said tumor cells are primary ductal carcinoma cells, leukemia cells, acute T cell leukemia cells, chronic myeloid lymphoma (CML) cells, acute myelogenous leukemia cells, chronic myelogenous leukemia (CML) cells, lung carcinoma cells, colon adenocarcinoma cells, histiocytic lymphoma cells, multiple myeloma cells, colorectal carcinoma cells, colorectal adenocarcinoma cells, or retinoblastoma cells.

17. The method of claim 12, wherein said PINK cells are contacted with an immunomodulatory compound in an amount and for a time sufficient for said PINK cells to express detectably more granzyme B than an equivalent number of PINK cells not contacted with said immunomodulatory compound.

18. The method of claim 17, wherein said immunomodulatory compound is lenalidomide or pomalidomide.

30. The method of claim 12, wherein said placental perfusate cells comprise at least about 50% CD56⁺, CD16⁻

PINK cells.

32. The method of claim 12, wherein said PINK cells express one or more of the microRNAs hsa-miR-100, hsa-miR-127, hsa-miR-211, hsa-miR-302c, hsa-miR-326, hsa-miR-337, hsa-miR-497, hsa-miR-512-3p, hsa-miR-515-5p, hsa-miR-517b, hsa-miR-517c, hsa-miR-518a, hsa-miR-518e, hsa-miR-519d, hsa-miR-520g, hsa-miR-520h, hsa-miR-564, hsa-miR-566, hsa-miR-618, or hsa-miR-99a at a detectably higher level than peripheral blood natural killer cells.

35. The method of claim 12, wherein said PINK cells express one or more of aminopeptidase N protein, apolipoprotein E protein, atrophin-1 interacting protein 1, innexin inx-3 protein, integrin alpha-2 precursor protein, integrin beta-5 precursor, mast cell surface glycoprotein GP49B precursor protein, or ryanodine receptor 1 protein;

and do not express one or more of fibroblast growth factor receptor 4 precursor protein, immunity-associated nucleotide 4-like protein, integrin alpha-L precursor protein, integrin beta 2 precursor protein, integrin beta 4 precursor protein, membrane-bound lytic murein transglycosylase D precursor protein, oxysterol binding protein-related protein 8, or perforin 1 precursor 1 protein.

19. A method of suppressing the proliferation of tumor cells comprising contacting the tumor cells with combined natural killer cells, wherein said combined natural killer cells comprise PINK cells isolated from placental perfusate and natural killer cells isolated from umbilical cord blood, and wherein said umbilical cord blood is isolated from the placenta from which said placental perfusate is obtained.

20. The method of claim 19, wherein said contacting takes place in vitro.

21. The method of claim 19, wherein said contacting takes place in vivo.

22. The method of claim 21, wherein said contacting takes place in a human.

23. The method of claim 19, wherein said tumor cells are primary ductal carcinoma cells, leukemia cells, acute T cell leukemia cells, chronic myeloid lymphoma (CML) cells, acute myelogenous leukemia cells, chronic myelogenous leukemia (CML) cells, lung carcinoma cells, colon adenocarcinoma cells, histiocytic lymphoma cells, multiple myeloma cells, colorectal carcinoma cells, colorectal adenocarcinoma cells, or retinoblastoma cells.

24. The method of claim 19, wherein said combined natural killer cells comprise:

a detectably higher number of CD3⁻

CD56⁺CD16⁻

natural killer cells than an equivalent number of natural killer cells from peripheral blood;

a detectably lower number of CD3⁻

CD56⁺CD16⁺ natural killer cells than an equivalent number of natural killer cells from peripheral blood;

a detectably higher number of CD3⁻

CD56⁺KIR2DL2/L3⁺ natural killer cells than an equivalent number of natural killer cells from peripheral blood;

a detectably lower number of CD3⁻

CD56⁺NKp46⁺ natural killer cells than an equivalent number of natural killer cells from peripheral blood;

a detectably higher number of CD3⁻

CD56⁺NKp30⁺ natural killer cells than an equivalent number of natural killer cells from peripheral blood;

a detectably higher number of CD3⁻

CD56⁺2B4⁺ natural killer cells than an equivalent number of natural killer cells from peripheral blood;

or

a detectably higher number of CD3⁻

CD56⁺CD94⁺ natural killer cells than an equivalent number of natural killer cells from peripheral blood.

25. The method of claim 24, wherein said natural killer cells have not been cultured.

26. The method of claim 19, wherein said combined natural killer cells comprise:

a detectably lower number of CD3⁻

CD56⁺KIR2DL2/L3⁺ natural killer cells than an equivalent number of natural killer cells from peripheral blood;

a detectably higher number of CD3⁻

CD56⁺NKp46⁺ natural killer cells than an equivalent number of natural killer cells from peripheral blood;

a detectably higher number of CD3⁻

CD56⁺NKp44⁺ natural killer cells than an equivalent number of natural killer cells from peripheral blood;

a detectably higher number of CD3⁻

CD56⁺NKp30⁺ natural killer cells than an equivalent number of natural killer cells from peripheral blood.

27. The method of claim 26, wherein said natural killer cells have been cultured.

28. The method of claim 27, wherein said natural killer cells have been cultured for about 21 days.

33. The method of claim 19, wherein said PINK cells express one or more of the microRNAs hsa-miR-100, hsa-miR-127, hsa-miR-211, hsa-miR-302c, hsa-miR-326, hsa-miR-337, hsa-miR-497, hsa-miR-512-3p, hsa-miR-515-5p, hsa-miR-517b, hsa-miR-517c, hsa-miR-518a, hsa-miR-518e, hsa-miR-519d, hsa-miR-520g, hsa-miR-520h, hsa-miR-564, hsa-miR-566, hsa-miR-618, or hsa-miR-99a at a detectably higher level than peripheral blood natural killer cells.

36. The method of claim 19, wherein said PINK cells express one or more of aminopeptidase N protein, apolipoprotein E protein, atrophin-1 interacting protein 1, innexin inx-3 protein, integrin alpha-2 precursor protein, integrin beta-5 precursor, mast cell surface glycoprotein GP49B precursor protein, or ryanodine receptor 1 protein;

and do not express one or more of fibroblast growth factor receptor 4 precursor protein, immunity-associated nucleotide 4-like protein, integrin alpha-L precursor protein, integrin beta 2 precursor protein, integrin beta 4 precursor protein, membrane-bound lytic murein transglycosylase D precursor protein, oxysterol binding protein-related protein 8, or perforin 1 precursor 1 protein.